Cart
sales@molnova.com
lorvotuzumab
CAS No. 339306-30-8
lorvotuzumab( —— )
Catalog No. M36882 CAS No. 339306-30-8
Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds to CD56 (NCAM1) and can be used to synthesize the antibody-drug conjugate Lorvotuzumab mertansine.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 559 | Get Quote |
|
| 5MG | 915 | Get Quote |
|
| 10MG | 1454 | Get Quote |
|
| 25MG | 2107 | Get Quote |
|
| 50MG | 2732 | Get Quote |
|
| 100MG | 3762 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product Namelorvotuzumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionLorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds to CD56 (NCAM1) and can be used to synthesize the antibody-drug conjugate Lorvotuzumab mertansine.
-
DescriptionLorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorADC Antibody
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number339306-30-8
-
Formula WeightApproximately 146.44 kDa.
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. James I Geller, et al. ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study. Cancer. 2020 Dec 15;126(24):5303-5310.?
molnova catalog
related products
-
Capitrol
Chloroxine is a synthetic antibacterial compound that is effective in the treatment of dandruff and seborrheic dermatitis when incorporated in a shampoo.
-
Hannokinol
(+)-Hannokinol and MESO-hannokinol can significantly inhibit lipopolysaccharide-induced nitric oxide production in BV2 microglial cells at concentrations ranging from 1 microM to 100 microM.
-
FFN 511
Fluorescent false neurotransmitter (FFN)
